iZafe Group (IZAFE-B) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached 2,434 TSEK, up 2.5x year-over-year, driven by Dosell and Pilloxa sales and new market launches.

• EBIT for the quarter was -4,148 TSEK, an improvement from -5,012 TSEK in Q3 2023; EBITDA was -3,166 TSEK.

• The number of active Dosell units increased by 29% sequentially, with approximately 2,000 units delivered to partners.

• Major milestones include a 500-unit Dosell order for Spain, new partnerships in Norway, and a three-party collaboration to enhance medication safety.

Financial highlights

• Net sales for Q3 2024 were 2,031 TSEK, up from 512 TSEK in Q3 2023; total revenue was 2,434 TSEK.

• Gross margin impacted by higher production and delivery costs as Dosell expanded into new markets.

• Net loss for the quarter was -4,955 TSEK, similar to -4,824 TSEK in Q3 2023; EPS was -0.02 SEK.

• Cash flow from operating activities for Q3 was -2,913 TSEK; cash and cash equivalents at period end were 3,238 TSEK.

• Equity per share at period end was 0.1 SEK; equity ratio was 58.0%.

Outlook and guidance

• Management expects continued growth, with clear forecasts to be presented from the next quarter based on active Dosell unit metrics.

• Expansion in Spain, Norway, and other European markets is expected to drive recurring revenue and market share.

• Liquidity for the next 12 months is considered secured, supported by recent financing and cost-saving measures.